Sanofi Pasteur Vaxdesign Corporation

Vaxdesign Corporation

Massachusetts Institute of Technology

The Scripps Research Institute

Mount Sinai School of Medicine

Children's Medical Center Corporation

Virginia Commonwealth University

Whitehead Institute for Biomedical Research

Whitehead Institute

Sanofi Pasteur Vaxdesign Corp. Et Al.

Guzman Sanchez-Schmitz

William L Warren

Heather Fahlenkamp

Russell Higbee

Anatoly Kachurin

Eric Mishkin

Conan Li

Donald Drake

Robert Parkhill

Darrell J Irvine

Michael D Rivard

John G Tew

Luis Mosquera

Mohey Eldin M El Shikh

Gwendalyn J Randolph

Mike Nguyen

Bruce Torbett

Selva Sukumar

Santosh Pawar

Nir Hacohen

Michael N Nguyen

Nir Harcohen

David Moe

Ofer Levy

Chad Stevens

Russel G Higbee

Russell G Higbee

Eric M Mishkin

Donald Iii Drake

Mohey Eldin El Shikh

Anatoly M Kachurin

Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.

Methods of evaluating immunogenicity of an agent using an artificial tissue construct

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Artificial immune system: methods of use

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

Methods for assaying responses to vaccines

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.

Methods for antibody production

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Methods of evaluating a test agent in a diseased cell model

Artificial immune system: methods for making and use

Methods of evaluating an immune response to an antigen

The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.

Disease model incorporation into an artificial immune system (AIS)

Artificial lymphoid tissue equivalent

In vitro germinal centers

Automatable artificial immune system (AIS)

Growing community of inventors

Orlando, FL, United States of America

Guzman Sanchez-Schmitz